Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Complexometric Titration: Ligands00:43

Complexometric Titration: Ligands

945
Different monodentate and polydentate ligands are used as complexing agents in complexometric titration reactions. The formation of complexes by mono- and bidentate ligands involves two or more intermediate steps, limiting their use as complexing agents. In comparison, polydentate ligands can form complexes with metal ions in a single-step process, facilitating sharper end points. This means polydentate ligands, such as amino carboxylic acid derivatives, are most commonly employed in...
945
Structural Isomerism02:34

Structural Isomerism

19.2K
Isomerism in Complexes
Isomers are different chemical species that have the same chemical formula. Structural isomerism of coordination compounds can be divided into two subcategories, the linkage isomers and coordination-sphere isomers.
Linkage isomers occur when the coordination compound contains a ligand that can bind to the transition metal center through two different atoms. For example, the CN− ligand can bind through the carbon atom or through the nitrogen atom. Similarly, SCN− can...
19.2K
Extraction: Advanced Methods00:56

Extraction: Advanced Methods

446
Metal ions can be separated from one another by complexation with organic ligands–the chelating agent– to form uncharged chelates. Here, the chelating agent must contain hydrophobic groups and behave as a weak acid, losing a proton to bind with the metal. Since most organic ligands used in this process are insoluble or undergo oxidation in the aqueous phase, the chelating agent is initially added to the organic phase and extracted into the aqueous phase. The metal-ligand complex is...
446

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ce(III) containing tricobalt-substituted silico-tungstate [CeCo<sub>3</sub>Si<sub>2</sub>W<sub>20</sub>O<sub>74</sub>(NO<sub>3</sub>)(OH)(H<sub>2</sub>O)]<sup>13-</sup>: a versatile nano-cluster with a multitude of applications.

Dalton transactions (Cambridge, England : 2003)·2026
Same author

Speciation Studies of Monosubstituted Pt, Mo, and W Decavanadates in Culture Media and In Vitro Activity Against Trypanosoma cruzi.

ChemMedChem·2026
Same author

The Thiol-Redox Biochemistry of Trypanosomatids: A New Perspective Based on Known and New Actors.

Biochemistry·2026
Same author

π-Radical Cascades to Peri-Fused Triangulene Dimers.

Angewandte Chemie (International ed. in English)·2026
Same author

Insights into the Chemico-Biological Interactions of Natural Sesquiterpene Lactones with the Thiol-Redox Metabolism of Pathogenic Trypanosomatids.

ChemMedChem·2026
Same author

Adamantane-thiazole hybrids and related derivatives: synthesis, crystal structures, in vitro antibacterial, antifungal, and anti-proliferative activities.

BMC chemistry·2026

Related Experiment Video

Updated: Jun 24, 2025

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology
07:07

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology

Published on: March 12, 2015

9.7K

Multifunctional Organometallic Compounds Active against Infective Trypanosomes: Ru(II) Ferrocenyl Derivatives with

Feriannys Rivas1, Carolina Del Mármol1, Gonzalo Scalese1,2

  • 1Área Química Inorgánica, Facultad de Química, Universidad de la República, 11800 Montevideo, Uruguay.

Inorganic Chemistry
|June 11, 2024
PubMed
Summary

New ruthenium (Ru) ferrocenyl compounds show potent in vitro activity against Human African trypanosomiasis and Chagas disease parasites. While effective in vitro, one compound demonstrated no acute toxicity but failed to control parasite proliferation in vivo.

More Related Videos

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

12.1K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.6K

Related Experiment Videos

Last Updated: Jun 24, 2025

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology
07:07

Synthetic Methodology for Asymmetric Ferrocene Derived Bio-conjugate Systems via Solid Phase Resin-based Methodology

Published on: March 12, 2015

9.7K
The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes
10:51

The Synthesis, Characterization and Reactivity of a Series of Ruthenium N-triphosPh Complexes

Published on: April 10, 2015

12.1K
An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles
09:00

An In Vitro Enzymatic Assay to Measure Transcription Inhibition by GalliumIII and H3 5,10,15-trispentafluorophenylcorroles

Published on: March 18, 2015

11.6K

Area of Science:

  • Medicinal Chemistry
  • Parasitology
  • Inorganic Chemistry

Background:

  • Human African trypanosomiasis (HAT) and Chagas disease are neglected tropical diseases caused by Trypanosoma parasites.
  • Current treatments for these diseases are limited, with few drugs available, often exhibiting poor safety and efficacy profiles.
  • There is an urgent need for novel therapeutic agents against these protozoan infections.

Purpose of the Study:

  • To design and synthesize novel multifunctional ruthenium(II) ferrocenyl compounds as potential anti-parasitic agents.
  • To evaluate the in vitro efficacy and selectivity of these compounds against Trypanosoma brucei and Trypanosoma cruzi.
  • To investigate the mechanism of action and preliminary in vivo therapeutic potential of the most promising candidates.

Main Methods:

  • Rational design and synthesis of Ru(II) ferrocenyl compounds incorporating dppf and bioactive ligands (mpo, NN).
  • Characterization of synthesized compounds using spectroscopic and analytical techniques.
  • In vitro anti-parasitic activity assays against bloodstream Trypanosoma brucei and Trypanosoma cruzi trypomastigotes.
  • Mechanism of action studies including DNA interaction, ROS generation, enzyme inhibition (fumarate reductase), and thiol oxidation assays.
  • In vivo efficacy assessment in a murine model of African trypanosomiasis.

Main Results:

  • Synthesized Ru(II) compounds exhibited potent in vitro activity against T. brucei (EC50 = 31-160 nM) and T. cruzi (EC50 = 190-410 nM).
  • Compounds demonstrated superior in vitro activity against T. brucei compared to previously developed metal-based agents and showed good selectivity.
  • Mechanism of action studies ruled out DNA interaction and ROS generation, implicating inhibition of T. cruzi NADH-dependent fumarate reductase.
  • A representative compound, [Ru(mpo)(dppf)(bipy)]Cl, showed no acute toxicity in vivo but failed to control parasite proliferation, likely due to pharmacokinetic limitations.

Conclusions:

  • Novel Ru(II) ferrocenyl compounds represent a promising class of agents with significant in vitro anti-parasitic activity against HAT and Chagas disease.
  • The compounds target specific parasitic pathways, such as T. cruzi fumarate reductase, distinct from traditional drug mechanisms.
  • Further pharmacokinetic studies and optimization are necessary to translate the in vitro efficacy of these compounds into viable in vivo therapeutic strategies.